Sunday 18 October 2026
Export ABOS’s income statement to Excel — free account
Acumen Pharmaceuticals, Inc.
ABOS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 33.8%, free cash flow grew 43.2% and total debt rose 5.65%, each against the same quarter a year earlier.
1.69
0.02
+1.20%
Follow ABOS
Acumen Pharmaceuticals, Inc. (ABOS) P/E ratio
Acumen Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.1× (June 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2020 | 0.0× | — |
| Sep 2020 | 0.0× | — |
| Jun 2020 | 0.0× | — |
| Mar 2020 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.1×
Ten-year median
0.0×
Current reading's percentile
86
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NRXP NRx Pharmaceuticals, Inc. compare | n/m |
| ARMP Armata Pharmaceuticals, Inc. compare | n/m |
| SPRB Spruce Biosciences, Inc. compare | n/m |
| VYGR Voyager Therapeutics, Inc. compare | n/m |
| OTLK Outlook Therapeutics, Inc. compare | n/m |
| ABOS Acumen Pharmaceuticals, Inc. | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HUMA Humacyte, Inc. compare | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)